Free Trial
NASDAQ:PETS

PetMed Express Q4 2025 Earnings Report

PetMed Express logo
$3.25 +0.13 (+4.17%)
As of 02:16 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

PetMed Express EPS Results

Actual EPS
N/A
Consensus EPS
-$0.02
Beat/Miss
N/A
One Year Ago EPS
N/A

PetMed Express Revenue Results

Actual Revenue
N/A
Expected Revenue
$51.10 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

PetMed Express Announcement Details

Quarter
Q4 2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

PetMed Express Earnings Headlines

The End of Elon Musk…?
The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.
Head to Head Comparison: PetMed Express (PETS) versus Its Peers
See More PetMed Express Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like PetMed Express? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PetMed Express and other key companies, straight to your email.

About PetMed Express

PetMed Express (NASDAQ:PETS) (NASDAQ: PETS) operates as an online retailer specializing in pet medications and related products. Founded in 1996 and based in Delray Beach, Florida, the company was one of the first to offer prescription and non-prescription pharmaceuticals for dogs and cats through its PetsWarehouse.com and 1-800-PETMED e-commerce platforms. Over the years, PetMed Express has expanded its product assortment to encompass parasite preventives, dermatology treatments, supplements, and health-related accessories, catering to the evolving needs of pet owners.

The company’s core offerings include FDA-approved prescription medications for chronic conditions such as arthritis, allergies, and heart disease, as well as popular over-the-counter products for flea, tick and heartworm control. In addition to pharmaceuticals, PetMed Express stocks food, treats, vitamins, grooming supplies, and other wellness items sourced from leading brands. The business model emphasizes convenience, allowing customers to upload veterinary prescriptions, set up recurring shipments for maintenance therapies and access online resources on pet health topics.

While PetMed Express primarily serves the United States, it maintains a presence in Canada through cross-border fulfillment partnerships and helps customers navigate import regulations for prescription products. The company leverages a vertically integrated distribution network, including its FDA-inspected warehouses and call center, to streamline order processing, ensure product authenticity and offer customer support. PetMed Express also invests in digital marketing initiatives, mobile app enhancements and telehealth pilot programs to strengthen client engagement and capture share of the growing online pet care market.

Founded and led by industry veteran Stephen M. Duerr, PetMed Express has adhered to a mission of improving pet health through accessible pet pharmacy solutions. The leadership team includes experienced professionals in logistics, quality assurance, regulatory affairs and information technology, underscoring the company’s commitment to compliance and customer satisfaction. Over more than two decades, PetMed Express has built brand recognition as a trusted resource for pet medications and wellness products.

View PetMed Express Profile

More Earnings Resources from MarketBeat